JP2017536812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536812A5 JP2017536812A5 JP2017520920A JP2017520920A JP2017536812A5 JP 2017536812 A5 JP2017536812 A5 JP 2017536812A5 JP 2017520920 A JP2017520920 A JP 2017520920A JP 2017520920 A JP2017520920 A JP 2017520920A JP 2017536812 A5 JP2017536812 A5 JP 2017536812A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- cell
- composition
- provides
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065138P | 2014-10-17 | 2014-10-17 | |
| US62/065,138 | 2014-10-17 | ||
| US201562151315P | 2015-04-22 | 2015-04-22 | |
| US62/151,315 | 2015-04-22 | ||
| PCT/US2015/056217 WO2016061574A1 (en) | 2014-10-17 | 2015-10-19 | Bipartite and tripartite signaling immune cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536812A JP2017536812A (ja) | 2017-12-14 |
| JP2017536812A5 true JP2017536812A5 (enExample) | 2018-11-15 |
| JP6821561B2 JP6821561B2 (ja) | 2021-01-27 |
Family
ID=55747478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520920A Active JP6821561B2 (ja) | 2014-10-17 | 2015-10-19 | バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170246278A1 (enExample) |
| EP (2) | EP3207147A4 (enExample) |
| JP (1) | JP6821561B2 (enExample) |
| MA (2) | MA41538A (enExample) |
| WO (1) | WO2016061574A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| CA2964958A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Methods and compositions for modified t cells |
| US10828353B2 (en) * | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| CA3030003A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| KR20230167769A (ko) * | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| US20190263928A1 (en) * | 2016-09-30 | 2019-08-29 | Baylor College Of Medicine | Adaptive chimeric antigen receptor t-cell design |
| GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CN118420783A (zh) * | 2017-12-06 | 2024-08-02 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| US20190192678A1 (en) * | 2017-12-18 | 2019-06-27 | Novather, Inc. | System and method for the treatment of disease using a hyperspecific modified protein system |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| WO2019156145A1 (ja) * | 2018-02-09 | 2019-08-15 | 国立大学法人大阪大学 | 改良されたαβＴ加工細胞製造方法 |
| MX2020009272A (es) | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| US12528856B2 (en) * | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| CN114981409A (zh) | 2019-09-03 | 2022-08-30 | 美洛德生物医药公司 | 用于基因组整合的方法和组合物 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| EP4182338A1 (en) | 2020-07-17 | 2023-05-24 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022197949A2 (en) | 2021-03-17 | 2022-09-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| BR112023023642A2 (pt) | 2021-05-11 | 2024-01-30 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
| WO2022266192A1 (en) | 2021-06-16 | 2022-12-22 | Instil Bio, Inc. | Receptors providing targeted costimulation for adoptive cell therapy |
| EP4370213A4 (en) | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| RU2573912C2 (ru) * | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
| CA2832569A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013329186B2 (en) * | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US10584158B2 (en) * | 2013-04-17 | 2020-03-10 | Baylor College Of Medicine | Immunosuppressive TGF-β signal converter |
-
2015
- 2015-10-18 MA MA041538A patent/MA41538A/fr unknown
- 2015-10-19 EP EP15850940.6A patent/EP3207147A4/en not_active Withdrawn
- 2015-10-19 JP JP2017520920A patent/JP6821561B2/ja active Active
- 2015-10-19 MA MA047580A patent/MA47580A/fr unknown
- 2015-10-19 EP EP18214778.5A patent/EP3489362B1/en active Active
- 2015-10-19 US US15/519,742 patent/US20170246278A1/en not_active Abandoned
- 2015-10-19 WO PCT/US2015/056217 patent/WO2016061574A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536812A5 (enExample) | ||
| Yan et al. | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment | |
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| JP6888225B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| Rezvani et al. | Engineering natural killer cells for cancer immunotherapy | |
| IL276593A (en) | Improved methods for producing adoptive cell therapies | |
| ES2671004T3 (es) | Dirección a CD138 en cáncer | |
| IL309526A (en) | TGFBeta signal converter | |
| Ruella et al. | Adoptive immunotherapy for cancer | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| JP2019535275A5 (enExample) | ||
| JP2021505131A5 (enExample) | ||
| RU2015116901A (ru) | Композиции и способы для имуннотерапии | |
| JP2022510207A5 (enExample) | ||
| JP2022548943A5 (enExample) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2019513347A5 (enExample) | ||
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| JP2016510597A5 (enExample) | ||
| JP2014512183A5 (enExample) | ||
| JP2017531687A5 (enExample) | ||
| JP2016520302A5 (enExample) | ||
| JP2017503472A5 (enExample) | ||
| CA2909701A1 (en) | Immunosuppressive tgf-.beta. signal converter | |
| EP3529353A1 (en) | Use of triplex cmv vaccine in car t cell therapy |